Ipriflavone

advanced glycation end products (AGE)

280.32

DMSO : 52 mg/mL (185.5 mM)
Ethanol : 2 mg/mL (7.13 mM)

白色至淡黄色结晶性粉末

Ipriflavone regulates the differentiation and biosynthetic properties of human bone marrow stromal osteoprogenitor cells (BMC) by enhancing the expression of some important matrix proteins and facilitating the mineralization process. Ipriflavone treatment at 10 μM significantly inhibits advanced glycation end products (AGE) enhanced bone resorption in cultured mouse unfractionated bone cells. In addition, Ipriflavone treatment potently enhances calcium uptake by duodenal cells. Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells in a dose-dependent manner, and blocks the ligand-induced phosphorylation of Tyr845 of the EGFR. Ipriflavone treatment at 50 μM does not induce apoptosis of MDA-231 cells.

Oral administration of Ipriflavone at 12 mg but not 6 mg significantly inhibits the development of new osteolytic bone metastases of MDA-231 cells, suppresses the progression of established osteolytic lesions, and reduces the number of osteoclasts adjacent to cancer cells in bone metastases. Consistent with the in vitro activity, Ipriflavone treatment at 6 or 12 mg/day significantly inhibits tumor growth of MDA-231 xenografts with 25% and 45% reductions by volume and 47% and 63% by weight, respectively, compared to untreated mice, and prolongs the life of tumor-bearing mice. LD50: Mice >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.); Rats >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.)

依普黄酮；Osteofix

C₁₈H₁₆O₃

35212-22-7